Ventyx Biosciences (NASDAQ:VTYX) Research Coverage Started at UBS Group

UBS Group assumed coverage on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research report sent to investors on Wednesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $20.00 target price on the stock.

VTYX has been the subject of a number of other reports. Oppenheimer downgraded shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday. Lifesci Capital restated a “market perform” rating and set a $14.00 target price on shares of Ventyx Biosciences in a research report on Thursday. Canaccord Genuity Group cut shares of Ventyx Biosciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $16.00 to $14.00 in a research note on Thursday. Wells Fargo & Company reissued an “equal weight” rating and set a $14.00 price target on shares of Ventyx Biosciences in a research note on Thursday. Finally, Piper Sandler cut Ventyx Biosciences from an “overweight” rating to a “neutral” rating and set a $14.00 price objective on the stock. in a report on Thursday. One research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ventyx Biosciences currently has an average rating of “Hold” and an average target price of $14.86.

Ventyx Biosciences Stock Down 0.2%

NASDAQ VTYX opened at $13.81 on Wednesday. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The business has a fifty day moving average of $9.27 and a 200-day moving average of $5.28. The stock has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, analysts anticipate that Ventyx Biosciences will post -2.09 EPS for the current year.

Insider Buying and Selling

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at $3,778,793.32. This trade represents a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total transaction of $365,503.40. Following the sale, the chief executive officer directly owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 14.49% of the company’s stock.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of Ventyx Biosciences by 925.6% in the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock valued at $1,012,000 after purchasing an additional 794,401 shares in the last quarter. Jane Street Group LLC purchased a new position in Ventyx Biosciences in the first quarter valued at approximately $56,000. Acadian Asset Management LLC raised its holdings in Ventyx Biosciences by 443.8% in the first quarter. Acadian Asset Management LLC now owns 537,054 shares of the company’s stock valued at $614,000 after buying an additional 438,286 shares during the period. Pallas Capital Advisors LLC acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $38,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Ventyx Biosciences by 21.1% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock worth $62,000 after buying an additional 5,174 shares during the period. 97.88% of the stock is currently owned by institutional investors and hedge funds.

Ventyx Biosciences News Roundup

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.